Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2018
Reporting Period: Events occurring on February 6, 2018, and February 28, 2018.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Expiration of Shareholder Rights Agreement: The Shareholder Rights Agreement dated February 5, 2008, and all associated preferred stock purchase rights expired by their terms on February 6, 2018. The agreement is no longer in force.
- Elimination of Preferred Stock Series: On February 28, 2018, the Company filed a Certificate of Elimination with the Delaware Secretary of State. This action eliminated the Series A Junior Participating Cumulative Preferred Stock.
- Capital Structure Adjustment: Shares previously designated as Series A Preferred Stock were returned to the status of authorized but unissued preferred stock, without specific series designation or rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a procedural report regarding corporate governance and capital structure changes.
Key Facts for Investor Verification
- Verify the expiration of the poison pill (Shareholder Rights Agreement) effective February 6, 2018.
- Confirm the filing of the Certificate of Elimination for Series A Preferred Stock with the Delaware Secretary of State.
- Review Exhibit 4.1 for the full legal text of the Certificate of Elimination.